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ABSTRACT  
Rheumatoid arthritis (RA), Psoriasis (Ps) and Psoriasis arthritis (PsA) are chronic 
inflammatory autoimmune disorders, where primary targets are peripheral joints, skin 
and skin/joints respectively. Both innate and adaptive immunity play a role in disease 
initiation and progression.  
 
B cell selection processes were studied by using a VDJ replacement mouse strain 
ACB (anti-C1 B cell mouse strain), which spontaneously produces anti-C1 
antibodies. C1 is one of the major, well-defined immunodominant epitopes on CII 
molecule. This model allowed for the first time to understand B cell tolerance 
mechanisms to CII, a matrix protein. We demonstrated that C1-specific B cells are 
neither negatively selected nor functionally anergized. Thus, this study contributed to 
better understanding of autoimmunity and pathogenesis of human RA. Tolerance 
mechanisms toward CII were explored using the classical collagen induced arthritis 
mouse (CIA) model. Interestingly, ACB mice were protected from arthritis 
development despite having elevated auto-antibodies in the sera. Introducing a 
mutation in the Ncf1 gene leading to ROS deficiency initiated arthritis that was 
associated with enhanced germinal centre (GC) formation, increased T cell responses 
and epitope-spreading of the CII-specific antibody repertoire. Hence, ROS mediated 
auto-B cell tolerance mechanisms might have important implications for understanding 
the epitope spreading events leading to onset of RA. 
 
A new mouse model of Ps and PsA in mice triggered by previously regarded non-
pathogenic mannan from Saccharomices cerevisiae was characterised. A new 
pathogenic pathway driven by macrophages and γδ T cells secreting IL-17A was 
demonstrated. Moreover, cutaneous and articular inflammation in mice was 
significantly increased under reduced oxidative environment. This novel Ps and PsA 
model could be extremely useful for testing new therapeutics for Ps and PsA patients. 
Different scoring techniques for Ps and PsA were evaluated in mice, in order to better 
assess disease severity for skin and joint inflammation in mannan induced model. This 
method will be most valuable to quantify disease activity for testing novel therapeutics.  
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1 THE IMMUNE SYSTEM 
The immune system organization is dependent on two-protection systems: non-specific 
responses (I) comprising anatomical and physiological barriers as the first line of 
defence and (II) innate immunity as the second line; specific responses-involving (III) 
adaptive (acquired) immunity [1] as summarized in figure 1. The interaction between 
these components of the immune system favours guarding of our body from 
invading/foreign microorganisms such as viruses, bacteria, fungi and protozoa [2].  
 
Figure 1. Schematic representation of the immune system with non-specific and specific 
defence mechanisms 
 
1.1 NON-SPECIFIC RESPONSES 
1.1.1 First line of defense 
Major anatomical barriers to microorganisms are the skin and the mucous membranes 
of the respiratory, gastrointestinal (GUT) system that are able to trap microbes and 
prevent their passage into our body. A variety of physiological secretions as tears, 
saliva or nasal secretions protect natural openings. The protective roles of the "normal" 
microbiota (microbial flora) which are growing on the skin and in the mouth, 
gastrointestinal tract, and other areas of the body do not cause disease, while their 
growth is kept under control by the host's defence mechanisms. When the growth of the 
“normal” microbial flora is suppressed, foreign, disease causing agents may be able to 
enter, infect and initiate the disease [1, 2]. 
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1.1.2 Second line of defense  
 
Innate immunity, an ancient component of the immune system, represents a non-
specific mechanism of the host defence, existing in all the multicellular organisms, 
while acquired immune system developed relatively later in only “higher” vertebrates. 
The most important cell types involved in innate protection system comprised of innate 
immune cells such as macrophages that detect, track, engulf, and kill the invading 
bacteria and viruses as well as infected host cells and other debris; neutrophils, 
dendritic cells, eosinophils, mast cell, natural killer (NK) cells and natural killer T cells. 
To supplement immune responses against microorganisms, additional help from 
humoral components is provided. For example: complement proteins and anti-
microbial peptides including defensins [1]. The most essential feature of the innate 
immunity is an immediate responsiveness to the microbial invasion, which is achieved 
through microbial components, designated as pathogen-associated molecular patterns 
(PAMPs). TLRs are a type of pattern recognition receptor (PRR) recognizing PAMPs 
[3]. PAMP-TLR interactions initiate intracellular signaling cascades, leading to the 
expression of different inflammatory molecules and thereby orchestrating the early 
defense response to infections [4]. TLRs are divided into sub-families depending on 
their recognition motifs. TLR1, TLR2, TLR4 and TLR6 recognize lipids, whereas 
TLR3, TLR7, TLR8 and TLR9 recognize nucleic acids [4]. Inflammation can be 
another non-specific defence mechanism that helps to prevent infectious agents 
spreading in the body. The inflammatory response involves redness (erythema), 
swelling (edema) and pain (dolor). But in certain conditions, inflammatory reactions 
can lead to tissue damage and disease induction. 
 
1.2 SPECIFIC RESPONSES 
 
1.2.1 Third Line: Adaptive immunity  
1.2.2 B cells  
B cell discovery took place in the mid-1960s and early 1970s using animal models. 
Max Cooper and Robert Good suggested a cell type in the chicken bursa of Fabricius, 
which is responsible for immunoglobulin (antibody) production. By using murine 
transplant models it was demonstrated that bone marrow (BM) derived cells mediate 
antibody responses [5]. 
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1.2.2.1 B cell development 
B cell development takes place in the BM, via a diverse repertoire of VDJ and VJ 
rearrangements encoding the BCR (B-cell receptor). The recombinase activating genes 
1 and 2 (RAG1/2) join a D and JH segment at the Ig heavy chain (IgH) locus, 
followed by VH to DJH rearrangement [6, 7] at pro-B cell stage of B cell 
development. Productively recombined VHDJH at IgH, pairs with surrogate light 
chain (λ5-Vpre-B) and forms the pre-BCR. This stage is called as large pre-BCR 
stage. The pre-BCR complex includes the Ig-α and Ig-β cell signaling components to 
the cell surface [8]. As a next step, light chain rearrangement occurs as part of the 
small pre-B cell stage. Successfull light chain rearrangement at either the Ig kappa (κ) 
or lambda (λ) light chain locus gives rise to the expression of a complete BCR, 
denoted as immature B cell stage, Imm-B (Figure 2) [8] Most of the B cell 
differentiation and Ig gene rearrangement data were obtained from mouse studies, but 
human B cell development is markedly similar. As in mice, human B cells arise in the 
fetal liver or BM and are continuously generated throughout life [9].  
 
There are at least 10 different transcription factors regulate B cell development at 
early stages. Among them, EBF, E2A and Pax5 are important in B-cell linage 
commitment and differentiation. Pax 5 can activate the genes, which are required for 
B-cell development and repress the once which are critical in non-B cell lineage cells. 
As a fact, Pax5 deficiency in mice leads to B-cell developmental arrest at the stage of 
transition from DJ to VDJ rearrangement [10].  
 
Figure 2. B-cell developmental stages in the bone marrow from CLP (common lymphoid 
progenitor) to ImmB (immature B cell) subsets (Adapted and modified from source: Tucker 
W. Lebien. 2008. Blood) [11].  
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1.2.2.2 B cell subsets 
B cells can be separated into two lineages: B-1, “innate-like” and B-2. It still remains 
unclear whether B-1 and B-2 cells are derived from a common progenitor [12]. 
Murine B-1 cells are derived primarily from the fetal liver and the self-renewal occurs 
largly in the periphery [13, 14]. In contrast, B-2 cells arise mostly from the bone 
marrow and are produced constitutively. Peritoneal B-1 cells are subdivided into two 
subsets: the B-1a (CD5+) and B-1b (CD5−), where B-1a cells produce so called 
“natural antibodies” providing protection towards bacterial infections, while B-1b 
cells contribute to long-term “adaptive antibody” responses to polysaccharides and 
other T cell–independent type 2 antigens during infection [15]. Notably, MZB cells 
are a unique population of murine splenic B cells residing (at least in mice) within the 
marginal zone of the splenic white pulp [16]. FOB cells are recirculating and are 
found in the blood and secondary lymphoid organs. Besides, FO and MZB cells 
display different signaling characteristics of BCR and serve distinct functions [16]. 
Cytokine milleu, BCR specificity and competition with pre-existing mature B cells 
are decisive factors for mature B cell subsets to dictate which B cell subsets they 
should enter. B-10 cells are specific IL-10-producing subset having regulatory 
function mediated by IL-10 (Figure 3). B10 cells share surface markers with other B 
cell subsets but currently there is no cell surface/intracellular marker, which is unique 
to B10 cells [17].  
 
Figure 3. B cell subsets: B1 (B-1a, B-1b), MZB (Marginal Zone B cells), FOB (Follicular B 
cells), B-10 cells 
 
1.2.2.3 B cell selection in the periphery 
After leaving the bone marrow, “transitional B cells” (T1 and T2) (immature B cells), 
respond to follicular dendritic cells (FDCs) bound T cell–dependent antigens. They 
get activated (Act-B), proliferate, and either differentiate into short lived plasma cells 
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(SL-PC), (extrafollicular origin) secreting low affinity abtibodies or enter GC 
reactions. Proliferating B cells move to the borders of B cell and T cell zones in the 
secondary lymphid organs (lymph nodes and spleen). These structures are called 
germinal centers (GCs); where T-cell dependent (TD) immune responses take place, 
which includes affinity maturation, memory B cell pool formation and long-lived 
plasma cell (LL-PC) generation [18, 19] (Figure 4). Commitment to the PC fate 
involves the expression of B lymphocyte induced maturation protein 1 (Blimp1), 
which extinguishes the mature B cell gene expression program [20]. Blimp1 initiates 
the PC transcriptional program and represses both Bcl6 and Pax5 [21]. Antigen 
specifc antibodies derived from long-lived plasma cells travel to the bone marrow and 
stay there for the lifetime without any need for self-replenishment [22, 23]. GC 
formation requires cognate interactions between activated CD4 T cells and antigen-
presenting B cells, which includes MHC class II-restricted presentation by the B cell, 
costimulation via CD40-CD40L and certain cytokines such as IL-21. A very 
important gene activated in GC B cells is activation-induced deaminase (AID), which 
induces point mutations in Ig V regions [24]. This is called as somatic hypermutation 
(SHM) and as a result clonal variants of GC B cells with altered antigen affinity and 
specificity are formed [25]. Higher affinity BCR bearing B cells for antigen are 
positively sellected, whereas those with lower affinity die by apoptosis [26]. AID also 
mediates class switch recombination (CSR) [24] (Figure 4).  
 
Figure 4. B cell sellection in the peripheral lymphoid organ, GC and non-GC reaction. Imm-B 
(immature B cell), FOB (follicular B cell), Act-B (activated B cell), SL-PC (short-lived plasma 
cell), Mem-B (memmory B cell), LL-PC (long lived plasma cell) and PB (plasma blast). 
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1.2.3 T cells 
 
To eliminate viral, bacterial or parasitic infections, T cels mediate adaptive immunity 
processes. Foreign or self-Ag recognition by T cells is based on the recognition 
through T cell receptor (TCR) of antigenic peptides which are presented by MHC 
molecules present on Ag-presenting cells (APC) [27] where the recognition of self-
Ag can lead to induction of different autoimmune inflammatory diseases. T cell-
mediated responses include 1) a primary response by naive T cells, 2) effector 
functions by activated T cells and 3) persistence of Ag-specific memory T cells. The 
activated T cells clonally expand and perform effector functions such as cell-
mediated cytotoxicity and secretion of different cytokines. Infected or malignant cells 
bearing the Ag are directly lysed by cytotoxic CD8+ T cells [28], while CD4+ T 
helper cells can produce cytokines that act toxic to the target cells or able to stimulate 
other T cell effector functions or B cell antibody production [29]. Naive T cells live 
for a short period and effector cells disappear at the end of the immune response. 
Memory T cells can survive for many years and upon activation can respond 
immediately in peripheral tissues or undergo activation and proliferation in lymphoid 
organs to mount a secondary immune response to already encountered Ag [30]. 
 9 
2 AUTOIMMUNITY 
Autoimmunity is a failure of the immune response enabling recognition of self-cells 
and tissues and as a result an aberrant immune response is formed towards own 
constituent parts of the body. The diseases, arising from such pathogenic immune 
grounds are referred as autoimmune diseases. 
 
2.1 AUTOIMMUNE DISEASES 
There are large number of immune disorders recognized as autoimmune diseases. A 
German-American immunologist, Ernst Wibetsky co-autored a paper in 1957, where 
the first formulation of autoimmune disease criteria’s, denoted as “Witebsky`s 
postulates” were published [31]. A recent modification to these standards were 
accepted in 1994 [32] as follows: a) Direct evidence from transfer of pathogenic 
antibody or pathogenic T cells; b) Indirect evidence based on reproduction of the 
autoimmune disease in experimental animals; c) Circumstantial evidence from clinical 
clues [32]. 
 
2.2 AUTOIMMUNE DISEASE CLASSIFICATION 
Autoimmune diseases are classified as organ-specific (localized) as in Celiac disease, 
Multiple sclerosis, Type 1 Diabetes, Ulcerative Colitis or systemic (involving several 
organs) as in Systemic Lupus erythematosus, Rheumatoid Arthritis, Scleroderma, 
Sjogren`s Syndrome. However, in certain conditions, organ specific disorder could be 
provoked by systemic autoimmunity [33]. 
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3 RHEUMATOID ARTHRITIS (RA) 
 
3.1 OVERVIEW 
Rheumatoid arthritis (RA) is an autoimmune, polygenic, systemic inflammatory 
disorder affecting up to 1% of the worldwide population [34]. Many different extra-
articular body tissues and organs are involved in the disease pathogenesis [35], but 
particularly, peripheral (synovial) joints are disturbed. This inflammatory disease 
causes pain and if not adequate care/treatment is provided, pathologic condition can get 
worsened, leading to loss of joint function and mobility.  
 
3.1.1 Clinical symptoms 
RA affected joint is symptomized with painful (dolour), stiff, swollen (edema), red 
(erythema) joints. Stiffness, lasting for over an hour in particular during morning, is 
also called as morning stiffness. Diseased joints are mainly symmetrically affected but 
at an initial phase of the disease it can be asymmetric too. In figure 5, arthritis affected 
hind paws in animal model of RA disease is shown.  
 
Figure 5. Representative images of a naïve and arthritic hind paws of mice. 
 
3.1.2 RA joint 
Arthritic joint is characterised by synovial inflammation (inflamed capsule around the 
joint), excess synovial fluid and pannus formation (fibrous tissue development) in the 
joint cavity [36]. Severe joint inflammation can lead to joint architecture distruction and 
ankylosis (fusion) of the joints. Arthritic mouse ankle joint histopathology is shown in 
figure 6. 
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Figure 6. Histopathology of a normal and arthritis diseased hind paw ankle joint. 
 
3.1.3 Epidemiology 
The overall prevalence of RA worldwide is approximately 0.5% to 1% but there is a 
large regional variation towards disease prevalence. Disease incidence seems to be 
highest in Pima Indians (5.3%) and Chippewa Indians (6.8%), and lowest in people 
from China and Japan (0.2%-0.3%), suggesting a possible role for specific risk 
factors such as genes and environmental triggers [37-39].  
 
3.1.4 Genetic susceptibility 
3.1.4.1 MHC genes 
Major histocompatibility complex (MHC) is the only region of the genome, which 
has been steadily shown to be associated with RA. In the HLA class II region are the 
HLA-DR, -DP and -DQ loci encoding the  and  chains of the various HLA class II 
molecules [40, 41]. In 1976 Stastny reported an association of RA with HLA-Dw4 
allele [42] but later on it was investigated that the different HLA-DR4 alleles are not 
equally associated with RA. Gregerson and co-workers suggested 'SE' hypothesis, 
which is an unifying hypothesis for the association of different HLA-DRB1 
specificities with RA. The alleles carrying this nucleotide sequence are DRB1*0401, 
*0404, *0405, *0408, *0101, *0102, *1402, *09 and *1001, where *0401 and *0404 are 
the predominant RA associated alleles in Caucasians. In contrast, there are other 
alleles that are negatively associated with RA and therefore have a protective role 
(DRB1*0103, *0402, *0802, *1302) [43]. 
 
Furthemore, there is a hierarchy of strength of the association of the different SE-
positive HLA-DRB1 alleles and RA. For example, the DRB1*0401/*0404 
heterozygote genotype is strongly associated with early disease onset and a more 
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severe disease phenotype than either DRB1*0401 or DRB1*0404 homozygosity [40]. 
 
3.1.4.2 Non-MHC genes 
There are number of non-HLA gene single nucleotide polymorphisms (SNPs) 
associated with RA [44]. The gene for the protein tyrosine phosphatase non-receptor 
type 22 (PTPN22) encodes the cytoplasmic lymphoid specific phosphatase (Lyp), 
which is a powerful inhibitor of T-cell activation [45]. A functional variant of 
PTPN22 has been recently shown to be associated with diffenet autoimmune 
disorders including RA. Additionally, correlation between PTPN22 and heavy 
cigarette smoking was shown [46]. Cytotoxic T lymphocyte-associated antigen 4 
(CTLA-4) is important for down regulation of T-cell activation and CTLA-4 gene 
polymorphisms have been implicated as risk factors for rheumatoid arthritis (RA), 
specifically in Chinese Han population [47]. The genome wide association studies on 
RA patients revealed a linkage with peptidyl arginine deiminase 4 (PADI4) genes. 
Case-control association studies and mRNA stability assays reported the association 
of PADI4 gene with RA in Korean and Japanese populations [48]. A meta-analysis 
showed a positive association between PADI4 and RA not only in the Japanese 
population but also in populations of European descent [49]. A polymorphism in 
chemokine receptor expressed by Th17 cells (CCR6) correlated with expression level 
of CCR6 mRNA and with the presence of IL-17 cytokine in the sera of RA patients, 
highlighting the importance of the Th17 pathway in RA pathogenesis [50]. TNF 
receptor-associated factor 1 (TRAF1), is encoded by the TRAF1 gene. TRAF1 
mediate the signal transduction through various receptors of the TNFR superfamily. 
A common genetic variant at the TRAF1-C5 locus on chromosome 9 is associated 
with an increased risk of anti-CCP-positive rheumatoid arthritis [51]. Recent meta-
analysis study show interferon regulatory factor 5 (IRF5) rs2004640, rs729302 and 
rs752637 polymorphisms association with RA susceptibility in Europeans and Asians 
[52]. The signal transducer and activator of transcription 4 (STAT4) is a critical 
molecule for the development of the Th1 cells. STAT4-mediated signaling promoted 
the production of autoimmune-associated components, which are implicated in the 
pathogenesis of autoimmune diseases, such as rheumatoid arthritis [53]. The Fc 
gamma receptor 3A (FCGR3A) polymorphism can predict response to biologic 
therapy in patients with rheumatoid arthritis as  investigated  by a meta-analysis [54]. 
Genotyping for these polymorphisms might be a good tool for personalized treatment. 
A large UK cohort study shows a strong association of CD40 gene, coding for the 
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costimulatory protein CD40 on antigen presenting cells, with susceptibility to RA 
[55]. Carriage of chemokine (C-C motif) ligand 21 (CCL21) risk alleles was 
associated with premature mortality in inflammatory polyarthritis, independently of 
anti-CCP antibody and SE status [56].  
 
3.1.5 Risk factors 
Varieties of risk factors have been identified as possible triggers of arthritis disease. 
RA is an age related disorder. It can occur at any age from childhood to old age, but 
usual onset is between 30 - 50 years of life. Gender has an importance in disease 
susceptibility; women are more prone to develop RA than men. It has been assumed 
that RA was linked to infections but Scher and colleagues show for the first time an 
association of a specific microbe to RA. Expansion of intestinal Prevotella copri, 
which is an intestinal gram-negative bacteria, correlated with an enhanced 
susceptibility to arthritis [57]. There have been several reports indicating that some 
periodontal pathogens such as Porphyromonas gingivalis are possible cause of RA 
[58]. Smoking contributes up to 25% of the population with a burden of developing 
RA. The risk is dose related, stronger in males and especially stronger for anti-
citrullinated peptide antibody positive (ACPA+) RA through an interaction with the 
shared epitope. The disease suusceptibility varies, which is much higher (35%) for 
ACPA+ RA group and up to 55% in individuals with two copies of the HLA-DRB1 
SE [59, 60]. Other associations are high coffee consumption and obesity, which may 
also increase RA risk [61]. Stress might exacerbate autoimmune disease by 
amplifying pro-inflammatory cytokine production [62]. Interestingly, occupational 
exposures, for example silica, have been associated with RA and to other 
autoimmune diseases. Silica is cytotoxic and produces inflammation in the lungs 
causing loss of self-tolerance and production of autoantibodies [63]. 
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3.1.6  Diagnosis and threatment 
According to 2010 ACR/EULAR classification criteria, RA is diagnosed based on 
following measurements: a) JOINT INVOLVEMNT (by counting the number of small 
and large joints affected); b) SEROLOGICAL FINDINGS (measuring RF and ACPA 
levels); c) ACUTE PHASE REACTANTS (CRP and ESR levels); d) DURATION OF 
CLINICAL SYMPTOMS [37]. 
 
3.1.6.1 First line “fast acting” drug therapy 
Non-steroidal anti-inflammatory drugs (NSAID-s) are used as first line medications to 
relieve pain and swelling by reducing the inflammation. Patients' response to different 
NSAID medications vary. NSAIDs block the production of prostaglandins (PGs) 
accomplished by inhibiting the activity of the enzyme cyclooxygenase (COX) [64]. 
Inhibition of COX-2 by NSAIDs blocks PG production at the site of inflammation, 
while inhibition of COX-1 can block PGs in other tissues, for example in gastro-
duodenal mucosa, potentially leading to common side effects such as bleeding and 
gastrointestinal ulceration [65]. Corticosteroid medications are more potent than 
NSAIDs in reducing inflammation and in restoring joint mobility and function [66]. 
Corticosteroids are used during severe flares of arthritis and are mainly given intra-
articularly (IA). 
 
3.1.6.2 Second line “slow acting” drug therapy 
First line medication is helpful to relieve joint inflammation and pain but they do not 
prevent disease progression. To better control the inflammatory processes, disease 
modifying anti-inflammatory drugs (DMARD-s) are used. Treatment with these 
"slow-acting" drugs will potentially take some time for its effectivness. 
Immunosuppressive medicines are powerful in suppressing the body's immune 
system [67]. A list of immunosuppressive drugs include cyclosporins, 
cyclophosphamide, myocrisin (gold injections), hydroxychloroquine, leflunomide, 
methotrexate, mycophenolate and sulfasalazine. Because of potentially serious side 
effects, immunosuppressive medicines (other than methotrexate) are generally used 
for those patients who have very aggressive disease [68]. 
 
3.1.6.3 Biological drug therapies 
In recent years, new drug therapies (biologics) have been developed to target 
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individual molecules. This type of therapy is more efficient than conventional 
DMARDs and is only given to DMARD therapy non-responders or to the patients 
with severe side effects. Biological therapies are often given in combination with 
methotrexate [67]. Anti–tumor necrosis factor (anti-TNF) therapies with adalimumab 
(a full monoclonal antibody), etanercept and infliximab (a chimeric monoclonal 
antibody) therapies have been routinely used as a treatment option of rheumatoid 
arthritis (RA) patients. However, about 30% of the patients abandon treatment with 
anti-TNF therapy within a year due to either side effects or the inefficacy of the 
treatment [69]. The second option is an alternative anti-TNF therapy [70-72] or anti-
CD20 therapy with Rituximab (RTX), a chimeric monoclonal antibody against the B 
lymphocyte surface marker CD20, introduced in 2006 for the medication of RA 
patients who have failed one or more anti-TNF therapies. RTX has been shown to be 
effective in different clinical trials [73, 74] and has been proven to cause circulating B 
cell depletion through antibody-dependent cell-mediated cytotoxicity, complement-
dependent cytotoxicity and apoptosis [75]. Abatacept, a human cytotoxic T-
lymphocyte antigen (CTLA)-4 and Fc-IgG1 fusion protein that blocks the 
costimulatory signal between CD28 and CD80/CD86 is approved for the treatment of 
active RA patients [76]. A humanised monoclonal antibody- Tocilizumab targeting 
the interleukin-6 receptor (anti-IL-6R) is another treatment option for RA. 
Tocilizumab blocks the downstream effects of IL-6 by affecting the function of 
neutrophils, T cells, B cells, monocytes, and osteoclasts and thereby the inflammatory 
cascade in RA [76].  
 
Blocking of complement-C5a, chemokines-CCL2, CCR1, cytokines-IL-10, IFN-beta, 
anti-CD4, anti-CD52 are experimental targeted therapies that are under consideration 
to be implicated in RA pathogenesis [77]. 
 
Despite having so many treatment options, there is no cure for the disease. Moreover, 
all these treatments are associated with many side effects as infections. The sites of 
infections associated with biological therapy are respiratory tract infections including 
pneumonia, septic arthritis, skin and soft tissue infections, and urinary tract 
infections. TNF plays an important role in the host defense mechanism against 
intracellular pathogens and consequently anti-TNF therapy is associated with 
increased risk of infection with intracellular micro-organisms such as Mycobacterium 
tuberculosis, Listeria monocytogenes and Legionella pneumophila [78, 79]. 
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4 AUTO-ANTIGENS IN RA  
A variety of different autoantigens has been described to be associated with human 
RA by identifying the reactivity to those antigens in the sera and synovial fluid. Most 
of these autoantigens can not be associated with RA patogenesis due to little 
experimental evidence or clinical observations. Autoantigens can be categorized as 
JOINT-associated autoantiges such as CII (Collagen type II), proteoglycans as well 
as HCgp-39 (human chondrocyte glycoprotein 39) [80] and NON-JOINT-associated 
autoantigens including HSPs (heat shock proteins), citrulinated fillagrin (post-
translationaly altered proteins) and ubiquitously expressed proteins such as GPI6 
(Glucoso-6-phosphate isomerase), P205 (contains an 11 aminoacid stretch identical to 
a sequence (278-288) located in the CH2 domain of immunoglobulin G (this domain 
contains the major epitopes of rheumatoid factors) and BiP (HSPs secreted duing 
stress) [80]. 
 
4.1 COLLAGEN TYPE II (CII), THE C1 EPITOPE  
Collagen type II (CII) is a major autoantigen in animal model of RA and belong to 
fibrilar forming collagen group together with type I, II, V and XI collagen. CII 
consists of 3 pro-alpha chains, which are assembled into triple helical molecule. After 
specific cleaving of non-helical ends with proteinases, triple helix is assembled into 
fibrils (Figure 7) [81].  
 
 
 
Figure 7. Simple illustration of CII fibril formation. 
 
Anti-CII monoclonal antibodies are capable of initiating arthritis in animal model of 
rheumatoid arthritis independent of B and T cells during the effector phase of arthritis 
[82]. There are different immunodominant epitopes on triple helical CII, recognized 
by autoreactive B cells.  
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The dominant and most characterized CII epitopes in CIA model are C1, U1, J1 and 
F4, and the monoclonal antibodies specifically recognising these epitopes are denoted 
as CB20 (IgG1) and CIIC1 (IgG2a), UL-1 (IgG2b), M2139 (IgG2b) and CIIF4 
(IgG2a) respectively [83]. These antibodies are not cross-reacting with other collagen 
types or the denatured CII. The structural integrity of CII epitopes for antibody 
recognition is very important. CIA is only induced by immunization with triple 
helical CII and not by the denatured one [84, 85]. 
 
Interestingly, not all the CII specific antibodies are having pathogenic capacity. 
Antibodies to C1, J1 and U1 epitops are arthritogenic, while CIIF4 antibody was 
shown to negatively associate with the CAIA disease model of arthritis. Pathogenic 
monoclonal antibodies have different degradative capacities in vitro. As an example, 
CII-C1 has destructive effect on cartilage synthesis and dissorganization of CII 
fibrils. UL-1 can induce inflammation-independent proteoglycan depletion in vitro, 
whereas M2139 induces thickening and aggregation of CII fibrils and abnormal 
morphology in chondrocytes [86-88].  
 
Among C1 epitope specific monoclonal antibody library, 40% of them are mainly 
recognizing certain amino acid sequence: GARGLTGROGDA (O = hydroxyproline) 
located at position 358–369 on CII in mice and human [89, 90]. Moreover, the 
arginine residues of C1 can be enzymatically modified by peptidyl arginine deiminase 
(PAD) enzymes to citrulline, and autoantibodies to citrullinated C1 have also been 
detected in RA [91].  
Earlier studies have shown that C1-specific antibodies (such as the well-
characterized, germline-encoded, CB20) were obtained from mice after the primary 
immunization with CII [92, 93]. 
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5 ANIMAL MODELS OF RA  
To identify the susceptible genes and pathological pathways in autoimmune RA, 
different animal models are used. By altering animal housing conditions, one can 
identify various environmental factors triggering disease and its development. There 
are several important criteriae of selecting animal models for the disease studies: a) a 
capacity to predict different therapeutic agents in humans, b) easy to perform, c) 
reproducibility of the data, d) duration of the test period and e) similarity to human 
disease pathogenesis. Mouse models of arthritis are classified as spontaneous and 
induced. 
 
5.1 SPONTANEOUS 
Spontaneous models of arthritis do not require any external trigger for disease 
induction. SKG - a mouse model of spontaneous arthritis caused by a ζ-chain–
associated protein kinase 70 (ZAP-70) mutation, which spontaneously develop into 
chronic arthritis. Synovial inflammation in affected joints resembles rheumatoid 
arthritis with an accompanying infiltration of CD4+ T cells with eroded cartilage and 
bone and mounting of autoantibodies including rheumatoid factor [94]. MRL/l mice 
spontaneously develop arthritis similar to human rheumatoid arthritis with synovitis 
and/or arthritis, presence of circulating IgM rheumatoid factor (RF) and demonstrable 
synovial and/or joint pathology [95]. TNFα  Tg-mouse over-expresses human TNF-
alpha and develops an erosive polyarthritis which has many characteristics of 
rheumatoid arthritis in patients. The TNFα-Tg mice are very useful tools to 
understand pathogenic mechanisms of arthritis and to evaluate the efficacy of novel 
therapeutic strategies for rheumatoid arthritis [96]. IL-1Ra k/o mice bred on the 
BALB/cA background, spontaneously develops inflammatory arthritis with many 
features resembling rheumatoid arthritis (RA) in humans [97]. IL-6R Tg mice have a 
homozygous mutation in the gp130 IL-6 receptor subunit and show enhanced signal 
transduction and STAT3 activation and develop RA-like joint disease [98]. In K/BxN 
mice, the expression of both the T cell receptor transgene KRN and the MHC class II 
molecule Ag7, results in the development of spontaneous arthritis [99]. The 
development of disease requires the presence of T and B lymphocytes and is 
dependent on the MHC class II molecule I-A(g7). B cell activation by antigen and an 
additional CD40-CD40 ligand interaction was found to give rise to production of 
 22 
autoantibodies. Glucose-6-phosphate isomerase was identified as the target of the 
autoantibodies; moreover, the transgenic T cells were demonstrated to exhibit a dual 
specificity for both bovine RNase and glucose-6-phosphate isomerase [100]. ACB 
mice, an IgH chain knock in mouse strain, spontaneously produce anti-C1 abs but do 
not develop spontaneous arthritis [101] and are relatively resistant to CIA. Only when 
ACB mice are bred to B10.Q/Ncf1** mice [a mutation in the Ncf1 gene in the B10Q 
mice impairs expression of the Ncf1 gene and totally blocks the function of the NOX2 
complexes) [102] brakedown of CIA resistance is operating during late phase of the 
disease, which was associated with epitope spreading on CII matrix. (Paper II). 
 
5.2 INDUCED 
In K/BxN serum transfer model, arthritis disease is serum transferable to normal 
recipients, which enables the examination of the pathogenic mechanisms of joint 
inflammation and destruction. Recent studies also suggest the importance of the 
innate immune system and its machinery such as complement components, Fc 
receptors and neutrophils, which are indispensable for disease induction [100]. GPI 
(Glucoso-6-Phosphate Isomerase)-induced arthritis is based on immunization with 
recombinant human G6PI, which results in polyarthritis that is dependent on MHC II 
and mouse genetic background [103]. Mice H-2q and H-2p MHC haplotypes are more 
prone to disease development [104]. In PgIA model of arthritis, immunization with 
chondroitinase ABC-digested fetal human cartilage proteoglycan and Freund's 
complete adjuvant induces polyarthritis and ankylosing spondylitis in female BALB/c 
mice. Clinicaly evident swelling and redness and histologicaly observed synovial 
inflammation of the paws was associated with mononuclear cell infiltration and 
perivascular concentration and occlusion of small vessels. Development of this 
arthritis was dependent on cell-mediated and humoral immunity to the immunizing 
antigen [105]. COMPIA-is a cartilage oligomeric matrix protein (COMP) induced 
arthritis, where immunization with rat COMP induced a severe, chronic, relapsing 
arthritis with a female preponderance in mice. This disease is strain dependent with 
high susceptibility in C3H.NB mice but not in B10.P mice, although they share the 
same MHC haplotype. Both H-2q and H-2p MHC haplotypes develop COMPIA. 
Interestingly, the transfer of anti-COMP serum was found to induce arthritis in naive 
mice. This model also provides a useful tool to study the pathogenesis of RA [106]. 
ZIA is an experimental animal model for human RA induced by injection of zymosan 
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into knee joints of mice. Within 7 days after intra-articular injection, a chronic 
inflammatory arthritis with mononuclear cell infiltration, synovial hyperplasia and 
pannus formation was observed [107]. 
 
5.2.1 CIA  
Collagen induced arthritis (CIA) is the most commonly used mouse model of 
rheumatoid arthritis, in which mice are immunized with CII in complete Freund´s 
adjuvant (CFA) at the base of the tail on day 0 and 5 weeks later a booster injection of 
CII in incomplete Freund´s adjuvant (IFA) is given. CIA model is shown to be 
dependent on T cells, APCs and B cells - particularly in the production of autoreactive 
antibodies toward auto-antigen CII. T and B cell deficient mice did not develop CIA 
[108-111]. Similar to human RA, CIA disease development is associated with MHC 
class II haplotypes. Mice having MHC H-2q haplotype are most susceptible for arthritis 
[112]. Similar to human arthritic joint, CIA paws are characterized with synovial 
hyperproliferation, cartilage and bone destruction [113]. The severity of joint 
destruction is dependent on tested mouse strain.  
 
5.2.2 CAIA  
Collagen antibody induced arthritis (CAIA), is commonly used animal model of 
arthritis, depicting the effector phase of arthritis. Autoreactive CII reactive antibodieas 
are generated from B cell hybridomas from mice previously immunized with CII [114, 
115]. Monoclonal CII-reactive antibodies are injected as a single dose or in the cocktail 
form using different concentrations depending on the mouse background used [114]. 
Within a week after antibody passive transfer, mice are boosted i.p. with bacterial 
lipopolysaccharide (LPS). The aim of LPS administration is to enhance the severity of 
the disease. The whole disease course lasts for 3 to 5 weeks. Contrary to CIA, CAIA 
can be induced in T and B cell deficient mice but the role of Fc gamma receptors and 
complement is crucial [116, 117]. Evenmore, for successful disease induction one need 
to consider monoclonal antibody specificity, isotype, concentration, antibody cocktail 
composition and the strain of the mice [114, 118]. 
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6 B CELL ROLE IN RA 
 
6.1 B CELL TOLERANCE CHECKPOINTS  
 
B cells play an important role in RA pathogenesis in many different aspects. B cell 
depletion therapies in humans [119] have shifted attention from macrophages and T 
cells towards B cells role in autoimmune diseases.  
 
In healthy individuals, most autoreactive B cells are eliminated from the body by two 
main mechanisms [120, 121]. A central B-cell tolerance checkpoint taking place in 
the bone marrow and removes the majority of autoreactive B cells expressing 
polyreactive phenotype. If some autoreactive B cells escape the central tolerance 
mechanisms, then a peripheral B-cell tolerance checkpoint takes over to further 
eliminate autoreactivity at emigrant/transitional B cell stage before they enter into the 
long-lived mature B cell pool. A large number of autoreactive B cells in different 
compartments in RA pathogenesis indicate that both central and peripheral B-cell 
tolerance checkpoints are not operating optimally and are defective in RA [121]. In 
untreated RA patients, the frequency of autoreactive transitional B cells in the blood 
was increased 3.4 - fold compared to control group, highlighting the inability of the 
immune system in central and peripheral lymphoid organs to remove polyreactive B 
cells [121]. 
 
There are 3 possible functions of B cells to contribute in RA pathogenesis: 
Autoantibody production - where B cells are the source of the rheumatoid factors, 
anti-CII and  anti-citrullinated protein antibodies, which contribute to immune 
complex formation and complement activation in the joints. Antigen presentation - 
where B cells can contribute to T cell activation through expression of co-stimulatory 
molecules. Cytokine secretion - where the chemokines and cytokines secreted can 
promote leukocyte infiltration into the joints, angiogenesis and synovial hyperplasia. 
 
6.2 AUTOANTIBODY PRODUCTION 
In RA, variable number of autoantigens are recognized by autoantibodies. The most 
studied autoantibodies are RFs (autoantibodies directed to the Fc portion of IgG) and 
ACPAs (anti-citrullinated protein antibodies). Autoreactive response towards self-IgG 
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usually occurs independent of T cell help and outside the GCs, while the response to 
citrulinated antigens develop through GC responses by acquiring T cell help. As it was 
shown, extrafollicular B cell responses are mainly regulated by TLR engagenment 
[122], but SHM and CSR of Ig genes, which mainly characterize T cell-dependent 
GC responses can also occur extrafollicularly upon TLR signaling. RF clones from 
RA patients are in fact somatically mutated compared to healthy subjects [123]. 
Although T cells are not required for the extrafollicular responses, they still help in 
amplifying and sustaining the chronic autoantibody production via CD40L and 
interleukin (IL)-21 signaling [122]. In contrast, immune response to citrullinated 
antigens is regulated via autoreactive T cells within established GC reactions. ACPA 
response is strongly associated with HLA DR alleles [124] and represent switched 
IgG-s generated from joint-derived B cells of RA patients [125]. 
 
6.3 ANTIGEN PRESENTATION 
B cells act as competent antigen presenting cells (APCs) to prime T cells and to 
develop memory CD4+ T-cell pool. B cells can selectively take up an antigen for 
presentation. As studies show, particularly RF+ B cells are important antigen 
presenting cells, where they can bind to antigen-Ig immune complexes via their 
surface Ig receptors specific to RF. After antigen processing, B cells then present 
peptides to T cells thereby inducing both T-cell activation and T-cell help [126].  
 
A good experimental evidence of T cell response dependency on B cell in RA 
synovium comes from Takemura et al. study, where it was shown that anti-CD20 
antibody treatment in RA synovial tissue xenotransplated SCID (immunodeficient) 
mice led to disruption of GCs, loss of follicular dendritic cell (FDC) networks, and 
impairment of T cell activation with a reduced production of T cell-derived cytokines 
[127]. It is tempting to speculate that there is a local cross-talk between citrullinated 
peptide-reacting B cells, which are functioning as APC for citrullinated peptide-
specific synovial T cells, based on the recent investigation where citrulinated peptide 
reactive B cells have been found to be enriched in RA joints [125]. 
  
Morover, B cells can stimulate pathogenic T-cell responses via cytokine secretion. B 
cells are a major source of IL-6 in the chronic phase of RA [128]. Mice, which were 
deficient in IL-6 production had mild arthritis severity together with impaired CD4+ 
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T cell produced IL-17 levels [129]. Notably, IL-6 inhibition increases the frequency 
of T-regs in both experimental and rheumatoid arthritis [130]. Recently, IL-6 is in 
fact been acknowledged as a major regulator of maintaining the balance between 
Th17 cells and T-regs. In turn, Th17 cells and their derived cytokines can promote B-
cell proliferation, differentiation, CSR and antibody production in vivo [131], which 
suggest that there might be a positive feedback loop between T and B cells potentially 
involved amplifying inflammatory responses. As shown, B-cell depletion affects both 
B cell and Th17 responses in vitro [132]. 
 
6.4 CYTOKINE PRODUCTION  
Accumulated data on B cell studies in autoimmune conditions indicate that B cells in 
RA can directly contribute to the local production of variable proinflammatory 
cytokines involved in the disease pathogenesis. B cells are major source for receptor 
activator nuclear factor kappa B ligand (RANKL) in the rheumatoid environment, 
suggesting their involvement in osteoclastogenesis. Latest reports have also shown 
that CD19+ B cells from both RA patients and healthy individuals are competent of 
producing IL-17A [133], possibly involved in different aspects of inflammation and 
bone damage. Evenmore, B cells infiltrating in the inflamed synovium may induce 
cytokine synthesis in the synovial fibroblasts through the production of IL-36α [134]. 
This study suggests tissue infiltrating B cells can interact not only with 
haematopoietic cells but also with the local stroma through paracrine mechanisms. 
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CHAPTER II 
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7 PSORIASIS (PS)  
7.1 OVERVIEW  
Psoriasis (Ps) is a common, chronic, immune-mediated, skin inflammatory disease 
recognized since early times when psoriasis, leprosy and other inflammatory skin 
disorders were erroneously thought to be the same condition [135]. Hippocrates was 
one of the first authors to write descriptions about skin disorders. He used the word 
lopoi to describe the dry, scaly and disfiguring eruptions of psoriasis, leprosy and other 
inflammatory skin disorders [136]. Psoriasis skin disorder affects up to 3% of 
worldwide population with equal sex distribution [137]. Disease development is higher 
in American and Canadian populations compared to Africans and Asians with a 
prevalence of 4.6-4.7% to 0.4-0.7% respectively [138]. Ps is considered to be organ-
specific autoimmune disease and it is possible to study its immunopathology and 
genomic features due to its occurrence in the accessible organ [139]. Psoriasis is a 
complex multifactorial syndrome, where different environmental triggers initiate the 
disease in genetically prone individuals. Additionally, patients with Ps disease have 
other disorders involving musculoskeletal structures, cardiovascular system, eye and 
the gut [140, 141].  
 
7.2 PS CLINICOPATHOLOGY 
Ps disease is usually manifested as erythematous, thickened plaques with silvery scales 
as shown in figure 1.  
 
Figure 1. Clinical phenotypes of Ps in mannan-induced Ps-like disease in mice. 
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Histopathologically, Ps is characterized by thickening of epidermis represented as 
acanthosis due to increased proliferation of keratinocytes with elongated rete ridges 
(ERR) (in humans only) protruded downward into the dermis. Incomplete maturation 
of epidermal keratinocytes results in abnormal retention of nuclei in the stratum 
corneum, denoted as parakeratosis (Figure 2) and inflammatory infiltrates in the 
epidermis (EPI). The dermis of the skin usually consists of DC, MF, Neutrophils and T 
cells [142]. Erythema of the Ps skin lesions is due to increased dilation of elongated 
blood vessels in the papillary dermal region. Moreover, endothelial cells are also 
activated in the Ps lesions via ICAM-1 (intracellular adhesion molecule), VCAM-1 
(vascular cell adhesion molecule) and E-selectin (CD62E) molecules [139]. 
 
Figure 2. Ps histopathology. PK (parakeratosis), Ac (acanthosis), ERR (elongated rete 
ridges), dashed line indicates the border between epidermis (EPI) and the dermis.  
 
7.3 PS GENETICS 
Ps disease susceptibility is complex. Population based studies showed higher disease 
inheritance in first/second degree relatives compared to the general population [143]. 
However, psoriasis propensity is never 100% among monozygotic twins, which argues 
for the influence of environmental factors on disease manifestation. Classic genome 
wide linkage analysis has mapped PSORS1 (psoriasis susceptibility 1) locus as a major 
genetic determinant [144]. PSORS1 is located on chromosome 6 in the MHC spanning 
within the class I telomeric region of HLA-B. It accounts for up to 50% of the 
inheritability of psoriasis [145]. HLA-Cw6, an associated variant of HLA-C is the 
susceptibility allele within PSOPS1 region [146]. Presence of HLA-Cw*0602 is 
associated with early onset and more severe Ps and it is found in 100% of patients with 
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guttate psoriasis [143, 147]. A genome-wide association study has identified sequence 
variants in the gene IL-23R and its ligand IL-12B conferring protection against 
psoriasis [148]. During inflammation, regulation of gene-expression network is 
controlled by microRNAs (miRNAs) via interfering with key inflammatory 
checkpoints [149]. It was shown that a distinct miRNA expression profile exists in 
psoriasis skin compared to healthy skin. For example, miR-203, miR-125b, miR-424 
and miR-99a regulate keratinocyte proliferation and differentiation, whereas miR-21 is 
up regulated in psoriatic skin and suppresses T cell apoptosis [149-152]. Suppression of 
miR-31 (a miRNA overexpressed in psoriasis keratinocytes) in psoriasis skin alleviated 
inflammation by interfering with the cross talk between the keratinocytes and immune 
cells [153]. 
 
7.4 TRIGGERS 
Any person can develop psoriasis but certain factors might increase the risk of 
triggering the disease in individuals having genetic predisposition as discussed 
previously. Infections: Various microorganisms such as bacteria (Streptococcus 
pyogenes, Staphylococcus aureus), fungi (Malassezia, Candida albicans) and viruses 
(papillomaviruses, retroviruses, endogenous retroviruses) are associated with triggering 
and/or exacerbation of psoriasis skin lesions [154, 155]. Skin infections are rare in 
psoriasis patients but infected tonsils might result in psoriatic lesions in the skin. Stress: 
Development and exacerbation of psoriasis can be influenced by emotional stress. 
"Stress responders" in psoriasis patients are considerably high ranging from 37% to 
78% [156]. Smoking: Based on recent meta-analysis, smoking is identified as an 
independent risk factor for the development of psoriasis and patients with established 
psoriasis continue to smoke more than patients without psoriasis [157]. Obesity: In 
1986, a Scandinavian study revealed a higher prevalence of obesity in psoriatic women 
than in healthy controls [158]. Neimann et al demonstrated that the risk of obesity was 
higher in patients with severe psoriasis than in those with moderate disease [159]. 
Medications: Surprisingly, few currently used medications such as Lithium (prescribed 
for bipolar disorder), anti-malarial agents (AMs) and Non-steroidal anti-inflammatory 
drugs (NSAIDs) can provoke or induce psoriasis symptoms [154, 160]. 
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7.5 CLINICAL VARIANTS 
 
7.5.1 Cutaneous manifestations 
 
Psoriasis can manifest into two different forms viz., cutaneous and extracutaneous. In 
cutaneous psoriasis different patterns are recognised depending on clinical 
manifestations and body part involvement [161]: Chronic Plaque Ps (psoriasis 
vulgaris) (CPP), which is the most common variant of the disease affecting 
approximately 85-90% of psoriasis patients [162] characterized by erythematous 
plaques with adherent silvery scale in the skin. Usually the scalp, elbows, knees and 
lumbosacral areas are involved [163]. Less common variants are Guttate Ps (GP) 
[164], Pustular Ps (PS) [165], Inverse Ps (IP), and Erythrodermic Ps (EP), 
(exfoliative psoriasis) [166]. Among extra-cutaneous forms, Nail psoriasis (NP) and 
Psoriasis arthritis (PsA) are recognized (Figure 3). 
 
Figure 3. Clinical variants of psoriasis (Ps). CPP (chronic plaque ps), GP (guttate Ps), EP 
(erythrodermic Ps), IP (inverse Ps), PP (pustular Ps), PsA (psoriasis arthritis) and NP (nail 
Ps). 
 
7.5.2 Extracutaneous manifestations 
7.5.2.1 Nail psoriasis (NP) 
Nail involvement in psoriasis patients was observed in 80% of the cases [167] affecting 
the nail matrix, bed, plate and the hyponychium (epithelium between the nail bed and 
nail plate). Psoriatic nail changes may include the following features: Pitting, 
Subungual hyperkeratosis/dystrophy, Oil spots and Onycholysis [163]. 
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7.5.2.2 Psoriatic arthritis (PsA) 
Psoriasis arthritis (PsA) is an inflammatory disease with an additional involvement of 
joints. It is a sero-negative arthritis and occurs in 6 to 26% of CPP patients [168]. In 
1973, Moll and Wright described five distinct patterns of PsA based on clinical 
presentations and distribution of the joint disease [169] as summarized in Figure 3: 
Asymmetric polyarthritis is the most common form affecting the distal joints in an 
asymmetric fashion involving only few joints (oligoarthritis). Symmetric polyarthritis 
is the peripheral joint disease, which is symmetrically distributed. 
Spondyloarthropathy, including sacroiliitis and ankylosis spondylitis. Predominant 
DIP involves distal interphalangeal joints. Arthritis mutilans with distal joint 
desorption. 
 
In recent years, extensive research provided novel insights into the mechanisms, which 
underlie and link both the skin and joint inflammation in PsA. As documented, the 
main pathological changes in PsA are associated with skin inflammation, synovial 
inflammation in the affected joints, enthesitis (enthesial inflammation), tenosynovitis 
(tendon sheath inflammation) and bone abnormalities. Until recently it was thought that 
psoriasis and psoriasis arthritis susceptible genes are the same but recent studies have 
shown that there are distinct genetic make-up between these two diseases. The gene 
MICA*002 is more specific to PsA than Ps. HLA-B38 and HLA-B39 are associated 
with peripheral PsA and HLA-B27 is more frequently identified in PsA with 
spondylitis [170]. Psoriatic arthritis patients with HLA-B27 or DQB1*02 were shown 
to have an increased risk of developing the most severe form of psoriatic arthritis as 
arthritis mutilans [171].  
 
7.6 DIAGNOSIS  
The diagnosis of psoriasis is mainly based on physical examination involving following 
criteria: a) Skin examination/inspection, determination of disease-involved sites and 
nail involvement, which is more common in psoriatic arthritis 2) A history of previous 
psoriasis or a family history of psoriasis. 3) Skin punch biopsy, which is a simple and 
effective way to confirm the diagnosis [163].  
 
Psoriasis severity can be categorized according to the Psoriasis Area and Severity 
Index (PASI) or the Physicians Global Assessment (PGA) [172]. PASI measures the 
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sum of both the severity of psoriasis and the percentage involvement of each body 
region with a 4-point scoring system. The intensity/severity of redness, thickness and 
scaling of the psoriasis is assessed as none (0), mild (1), moderate (2), severe (3) or 
very severe (4). The PGA measures psoriasis on a 7-point scale from clear (0) to very 
severe (6).  
 
It is of crucial importance to diagnose PsA as early as possible because early 
recognition of the disease will lead to treatment and consequently this might reduce 
irreversible joint damages. The most widely used ClASsification criteria for Psoriatic 
ARthritis (CASPAR) diagnostic system is applied for patients having inflammatory 
articular disease involving joints, spine or enthesis and ≥3 points using CASPAR 
system [173] is considered as positive identification as described in table 1. 
 
Table 1. ClASsification criteria for Psoriatic ARthritis (CASPAR) [173].  
 
7.7 TREATMENT 
There is no cure for psoriasis disease and all the available treatment options are aimed 
only to control the severity of the disease. These treatments are divided into 5 main 
categories: Topical treatment agents (lotion, gel, cream and ointment) are mainly used 
when Ps affected body surface area is less then 10%. This first line of medication can 
possibly be used as a monotherapy or in combination with other treatment options such 
as phototherapy and systemic medication [174]. Intralesional steroid injection is used 
to deliver the medications into skin lesions, to provide prolonged therapy and thereby 
minimizing the adverse effects of systemic therapy [163]. Phototherapy is usually used 
for both extensive and moderate Ps diseases. It consists of ultraviolet B (UVB) 
radiations, where NB-UVB (Narrow-Band UVB) may provide a faster rate of 
remission. Also, Ultraviolet A (UVA), which penetrates deeper into the skin and is 
mostly combined with the drug Psoralen (acting as a photosensitizer and increases the 
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local effect of UVA-treatment), so called PUVA treatment [163]. Patients with 
moderate to severe Ps, when more than 10% of body surface area is affected, and/or 
non-responders to topical/phototerapy are subjected to systemic treatment with 
methotrexate, acitretin or cyclosporine, or in combination with biologics including 
anti–tumor necrosis factor (anti-TNF) therapies, such as adalimumab (a full 
monoclonal antibody), etanercept and infliximab. Secukinumab, a recombinant, high-
affinity, fully human immunoglobulin monoclonal antibody that selectively neutralizes 
interleukin-17A showed the efficacy and safety in two randomized, phase 3 trials in 
patients with moderate-to-severe plaque psoriasis [175]. Another human monoclonal 
antibody Brodalumab, against interleukin-17 receptor A (IL17RA), was tested in a 
phase 2, randomized, double-blind, placebo-controlled study and showed significantly 
improved response among patients with psoriatic arthritis [176]. Also, alefacept (a fully 
human LFA3-IgG1 fusion protein targeting CD2) and ustekinumab (a fully human 
mAb targeting p40 subunit of IL12/IL-23) may be used in the combination therapy 
[177]. 
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8 IMMUNOPATHOLOGY OF PS AND PSA 
It is well acknowledged that both innate and adaptive immunity play a functional role 
in psoriasis pathology and in their interactions with keratinocytes.  
 
8.1 NON-IMMUNE CELLS  
Keratinocytes have a key function in balancing skin homeostasis. They serve as 
sentinels of the skin and protect our body against invading pathogens. Keratinocyte 
activation via TLR/NLR leads to predominant Th1-type immune responses with type I 
interferons (IFNs) secretion [178]. Keratinocytes may have anti-microbial activity by 
producing anti-microbial peptides (AMPs) like, psoriasin (S100A7), HBD-s (human β-
defensin-2 and human β-defensin-3) and LL-37 (Cathelicidin) [179, 180]. 
Keratinocytes can secrete pro-inflammatory cytokines and chemokines such as IL-1, 
IL-6, CXCL8, CXCL10 and CCL20 in response to different cytokine stimulations 
produced by innate and adaptive cells and additionally secreted anti-microbial peptides, 
which form chemotactic gradients to attract immune cells into the skin tissue [180]. 
Furthermore, keratinocytes express MHC class II molecules and might act as non-
professional antigen-presenting cells (APCs) [181]. 
 
8.2 INNATE IMMUNITY 
 
8.2.1 Monocytes/macrophages 
Monocytes/macrophages (Mo/MF) are divided into three major groups based on their 
functional properties: M1 macrophages, M2 macrophages and wound–healing 
macrophages [182], where M1 macrophages play an important role in both acute and 
chronic inflammation of the skin [183-185]. Psoriatic skin contains a large number of 
MF-secreting pro-inflammatory cytokines such as IL-6, IL-12 and IL-23 as described 
previously [186, 187]. Also, MF is the major source of TNF-α, which is involved in the 
activation of IL-17A driven inflammatory pathways and consequently triggering 
Ps/PsA like-inflammation in mice [185].  
 
8.2.2 Neutrophils and mast cells 
Neutrophils and mast cells play an important role in Ps and PsA pathogenesis. In 
mannan induced Ps/PsA model, granulocyte infiltration was observed in the psoriatic 
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skin and peritoneal cavity. Anti-Ly6G treatment had suppressing effect on both skin 
and joint lesions [185]. Neutrophils together with mast cells are normally found in the 
infiltrations of psoriatic plaques, where mast cells and neutrophils but not the T cells 
are the main source for IL-17 secretion in the human skin. IL-17 (+) mast cells and 
neutrophils are found at higher densities than IL-17 (+) T cells in psoriasis lesions 
[188]. But it is still debatable whether positive staining for IL-17 in these cell types is 
due to its secretion or uptake.  
 
8.2.3 Dendritic cells 
Dendritic cells (DC) are another sentinels of the immune system that bridge innate and 
adaptive immunity. They are normally found in both the layers of the skin: LCs 
(Langerhans cells) in the epidermis and, myeloid DC (mDC) and plasmacytoid DC 
(pDC) in the dermis [189]. In the dermis an increased number of CD11c+ mDC s were 
found that are secreting pro-inflammatory IL-12 and IL-23 cytokines. These mDC 
might be the immigrant cells derived from circulating DC precursors that are migrated 
and trapped in the skin in response to chemo-attraction [189] induced by AMPs and 
chemokines produced by keratinocytes [180]. pDC cell numbers are also significantly 
increased in Ps skin. They are mainly activated via TLR signalling. pDC produces large 
amount of IFN-α in response to self-DNA-LL37 complexes targeting TLR9, or self-
RNA-LL37 complexes recognizing TLR7 and TLR8.  Self-DNA/RNA fragments itself 
are released by the dying cells in the skin [190, 191].  
 
8.2.4 γδ T cells 
γδ T cells have important role in skin inflammation. They provide protection towards 
skin invading agents through production of IFNγ and IL-17. Mouse IL-17-producing γδ 
T cells were shown to be important in imiquimod (IMQ)-induced Ps and mannan-
induced Ps/PsA models [185, 192]. In IMQ-model, opposing effects of IL-15 and IL-
15Rα were shown in the psoriasiform skin inflammation, where IL-15 was responsible 
for the expansion of IL-17-producing γδ (and αβ) T cell populations and inhibited by 
keratinocyte-derived soluble IL-15 receptor antagonist [193]. Even more, CCR6 was 
required for epidermal trafficking of γδ-T cells in the IL-23-induced model of 
psoriasiform dermatitis [194]. Recent investigations showed that IL-23 from 
Langerhans cells was necessary for the development of IMQ-induced Ps-like dermatitis 
by induction of IL-17A-producing γδ T Cells [195].  
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8.3 ADAPTIVE IMMUNITY 
 
8.3.1 T cells 
T cells are considered to be the major mediators of Ps based on previous studies, which 
demonstrated lymphocyte inhibition and T cell–specific immunosuppressive 
(cyclosporine) treatments led to clinical improvement of the patients [196, 197]. Ps was 
shown to be Th1 driven pathology but later on another cytokine was discovered to be 
crucial for disease development. This cytokine has a p19 protein paired to IL-12 p40 
subunit (p40 is a shared subunit between IL-12 and IL-23 cytokines) and forms a new 
cytokine called IL-23. In the psoriatic skin, levels of IL-23 p19 and p40 subunits but 
not IL-12 p35 subunit are increased [198]. Depending on the cytokine milieu, T cells 
can be profiled differently. IL-23 was shown to activate T cells that expressed different 
cytokine profile such as IL-17A and IL-17F termed as Th17 cells and IL-22 expressing 
T cell subsets called Th22. Both Th17 and Th22 cells are influenced by the cytokine 
IL-23, which is required for their expansion and maintenance, which were shown to be 
involved in Ps pathogenesis [199, 200]. Thus IL-23-mediated Ps-like inflammation in 
the skin is IL-17A dependent [201], where IL-17A and other Th17 effector cytokines 
can lead to keratinocyte activation and further production of inflammatory mediators, 
all of which help in maintaining the psoriatic lesions. There are different models of Ps 
available to understand disease immune mechanisms. IL-22 overexpressing transgenic 
mouse has aberrant skin phenotypes mimicking psoriasis [202]. It was shown that in 
the absence of IL-22, IL-23-mediated dermal inflammation is reduced [203]. Recently 
it was shown in the IMQ-induced psoriasiform skin inflammation model, skin 
pathologies were almost absent after daily applications of imiquimod in the IL-22-
deficient mice and also in mice treated with blocking anti-IL-22 Abs [204]. A novel 
type of Th cells, designated as Th9, was identified recently but little information is 
available about these cells in humans. Recently, Schlapbach et al., showed that most of 
the memory Th9 cells are skin-tropic or skin-resident. IL-9-producing T cells were 
increased in the skin lesions of psoriasis, suggesting that these cells may contribute to 
human inflammatory skin disease. They also demonstrated that IL-9 was necessary for 
efficient production of IFN-γ, IL-9, IL-13 and IL-17 by skin-tropic T cells. Authors 
suggest that human Th9 cells may have protective function in the skin, but anomalous 
activation of these cells may contribute to skin inflammatory diseases [205]. 
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9 ANIMAL MODELS OF PS AND PSA 
 
9.1 SPONTANEOUS MODELS  
 
Various attempts have been made by researchers to establish animal models of 
cutaneous and articular inflammation resembling Ps and PsA to mimic human diseases. 
There are a number of spontaneous models available such as Flaky skin mice [206], 
which have a spontaneous mutation inducing increased squamous proliferation but 
without T-cell infiltration and keratinocyte hyperproliferation [207]. Similarly, 
spontaneous mutation in CPD (Chronic Proliferative Dermatitis) 
(Sharpincpdm/Sharpincpdm) mice induces skin lesions at the age of 5 to 6 weeks [208]. 
These lesions are characterized by epidermal hyperplasia, hyper- and parakeratosis and 
necrotic keratinocytes. Dermis and epidermis were infiltrated by granulocytes and 
macrophages [208] and skin inflammation was mainly dependent on Th2 cytokines 
(IL-4, IL-5, IL-13) but responded to IL-12 treatment [209]. Another spontaneous model 
is aging male DBA/1 mice, which develops spontaneous arthritis with some shared 
features of PsA in humans such as dactylitis, ankylosing enthesitis and 
onychoperisotitis [210] (Figure 4).  
 
9.2 GENETICALLY ENGINEERED MODELS  
A transgenic mouse model, designated as K5.Stat3C is a genetically manipulated strain, 
where signal transducer and activator of transcription (STAT) 3 was constitutively 
activated in basal keratinocytes under the control of the keratin 5 promoter (K5.Stat3C) 
[211]. Ps-like skin inflammation in this model was dependent on keratinocytes and T 
cells [211]. CD18 β2 Integrin hypomorphic mice have a decreased expression of 
common β2 –chain of lymphocyte integrin adhesion molecules. On PL/J strain 
background PL.129S7-Itgb2(tm1Bay) mice develop Ps-like skin inflammation with 
infiltrating lymphocytes having non-psoriasiform epidermal hyperplasia and also 
lacking hyper-proliferative keratinocytes [212, 213]. JunB/c-Jun epidermal inducible 
double knockout mouse represents another model, where targeting of epidermal 
keratinocytes led to Ps-like phenotypes and arthritic lesions. In contrast to the skin 
phenotype, development of arthritis required adaptive immune cells and signalling 
through tumour necrosis factor receptor 1 (TNFR1). Thus, epidermal alterations were 
sufficient to initiate both cutaneous and articular diseases [214]. Another PsA model by 
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Bardos et al described and characterized PsA-like disease in “humanized” (HLA 
transgenic) mice lacking their own major histocompatibility complex (MHC). Animals 
of 4 transgenic lines (HLA–DR2.Ab0, DR4.Ab0, DQ6.Ab0, and DQ8.Ab0) developed 
severe PsA-symptoms such as hyperkeratosis and parakeratosis, nail deformities and 
bone desorption associated with significantly fewer CD4+ cells in the peripheral blood 
and, reduced NK cell activity compared to disease resistant HLA–DR3.Ab0 transgenic 
mice [215]. Mice overexpressing VEGF epidermally via K14 promoter develops Ps-
like inflammation including vascular, epidermal and inflammatory features with an 
increased infiltration of mast cells in the upper dermis, and increased leukocyte rolling 
and adhesion in the post-capillary skin venules [216]. Epidermal specific deletion of the 
IKK2, which is a catalytic subunit of the IκB kinase complex (necessary for NF-κB 
activation through pro-inflammatory signals) causes Ps-like cutaneous inflammation 
similar to human Ps, including dependency on TNF signalling but independent of alpha 
beta T-cell-mediated inflammatory responses [217]. Keratin 14 promoter AR gene 
(K14-ARGE) has been shown to induce an early-onset and severe skin pathology 
characterized by hyperkeratosis with focal parakeratosis, acanthosis, lymphocyte and 
neutrophilic infiltration and vasodilation, which suggests that aberrant epidermal 
expression of AR might play a critical role in the development of psoriatic lesions 
[218]. In the follow up study by Cook et al., involucrin enhancer/promoter-dependent 
expression of human AR (INV-AR) in the supra-basal epidermis of transgenic mice 
also depicted the Ps-like phenotype. Histopathologically, INV-AR mouse also showed 
epidermal hyperkeratosis, parakeratosis, acanthosis, an exaggerated dermal vasculature 
and, infiltrated neutrophils and CD3(+) T lymphocytes in the lesions [219]. 
Interestingly, young K14-ARGE transgenic mice displayed synovitis with lymphocyte 
infiltration, increased vascularization and enhanced deposition of fibrous matrix in the 
knee synovium, while INV-AR transgenic mice knee joint did not have any of these 
abnormalities. Thus, epidermal AR expression is a possible mediator of cutaneous 
inflammation and also a potential trigger of both cutaneous psoriasis and psoriatic 
arthritis (Figure 4). 
 
9.3 INDUCED MODELS 
Imiquimod (IMQ), a topical application targeting TLR7/8 can induce and exacerbate 
IL-23/IL-17 axis dependent psoriasis in mice. IMQ-induced inflamed scaly skin lesions 
resemble plaque type psoriasis showing increased epidermal proliferation, abnormal 
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differentiation, CD4+ T cells, CD11c+ dendritic cells, plasmacytoid dendritic cells and 
neutrophils infiltration along with neo-angiogenesis. Also, epidermal expression of IL-
23, IL-17A and IL-17F, and an increase in splenic Th17 cells were noted [220]. 
Recently, we have developed a new disease model, in which a single intraperitoneal 
injection of Saccharomyces cerevisiae mannan induced psoriasis and psoriasis arthritis-
like symptoms in mice (Paper III & IV). Reactive oxygen species determined the nature 
of the developed disease. Erythema and edema of joints start one-day post-injection, 
reaching maximum severity on days 4-5, while skin scaling appears from day 3. This 
model depicts inflammatory phase of psoriasis arthritis, where macrophages and γδ-T 
cells, and IL-17A are the major contributors. Treatment with clodronate liposomes, 
anti-Ly6G and neutralization of IL-17A and TNF-α either completely blocked or 
significantly attenuated both joint and skin inflammation [185]. 
 
9.4 HUMAN SKIN TRANSPLANT MODELS 
In human skin transplant models, so-called xenotransplantation models, skin biopsy 
from Ps patient or in vitro cultured skin is transplanted into the mice. As a recipient 
strain for human skin transplants, severe combined immuno-deficient (SCID) and 
AGR129 mice are used [221, 222]. In these mice, grafted tissues were well tolerated 
and psoriatic characteristics were maintained for several months in the transplants 
[222]. Boyman et al. demonstrated that human uninvolved psoriatic skin grafted onto 
AGR129 mice spontaneously developed psoriatic plaques without injection of activated 
immune cells or any other exogenous factors [221]. Grafted skin histopathology was 
comparable to Ps lesions from the same patient [222] (Figure 4).  
 
9.5 IN VITRO MODELS 
An alternative approach to study Ps pathogenesis is by using in vitro models. However, 
contrary to in vivo models they have limitations. In the in vitro system epidermal 
keratinocytes obtained either from psoriatic or healthy individuals are grown at an air-
liquid interface where they differentiate and mimic the morphology of the stratified 
squamous epidermis. Keratinocytes are then treated with different factors (growth 
factors/cytokines) to develop psoriatic epidermis characteristics. This system can be 
used for studying keratinocyte behaviour towards different stimulation agents [223] 
(Figure 4). 
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Figure 4. Mouse models of Ps and PsA grouped as spontaneous, genetically engineered, 
induced, human skin transplant and in vitro models. 
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10 ROS IN PSORIASIS 
 
10.1 OVERVIEW 
Reactive Oxygen Species and reactive nitrogen species (ROS/RNS) describe oxygen 
derived reactive molecules, free radicals and nitrogen-containing oxidants with one or 
more uncoupled electrons. ROS generation as a by product occurs with mitochondria, 
peroxisomes, cytochrome P-450 and other cellular elements, however, the phagocyte 
nicotinamide adenine dinucleotide phosphate (NADPH oxidase) was the first identified 
example of a system that generates ROS not as a by product, but rather as the primary 
function of the enzyme system. The phagocyte NOX family of NADPH oxidases 
consist of NOX complexes (NOX1-5) and dual oxidase complexes (DUOX1-2) [224]. 
These enzymes are participating in reactive oxygen species (ROS) generation by 
transporting electrons across the plasma membrane. It was originally thought that 
phagocytic cells were responsible only for ROS production as part of the defence 
mechanism against invading pathogens but later it has also been demonstrated that 
ROS have a role in cell signalling including apoptosis, gene expression and in the 
activation of cell signalling cascades [225]. Overproduction or inadequate removal of 
ROS can result in oxidative stress leading to cell and tissue pathological changes due to 
damages in lipids, proteins and DNA [226]. In 1957, Berendes et al. [227] described a 
rare syndrome, triggered by pyogenic infections, now referred as chronic 
granulomatous disease (CGD) [228] caused by the absence of respiratory burst in the 
phagocytes of CGD patients. Patients with this genetic disorder suffer from life-
threatening infections [229]. It was found that in CGD patients, all the subunits in NOX 
complexes have mutations [230] [231]. The accepted view from early studies is that an 
insufficient anti-oxidant system together with increased levels of ROS leads to 
pathological changes in cells and tissues, as in inflammatory skin conditions. Oxidative 
stress is believed to be a key factor in the pathogenesis of psoriasis [226]. It is well 
evidenced that polymorphonuclear (PMN) infiltrates are present in the dermis of 
psoriatic lesions [232], where many factors could play a role in chemo-attraction of 
PMN into psoriatic lesions. According to one theory, ROS discharged by keratinocytes, 
fibroblasts and endothelial cells have chemotactic effects on neutrophils [233] and 
accumulation of neutrophils in psoriatic lesions may cause abundant superoxide 
production during phagocytic processes [234]. 
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10.2 THE PHAGOCYTE NADPH COMPLEX 
In a resting condition, the catalytic core of the phagocyte NADPH complex is 
composed of an enzymatic part - flavocytochrome b558, which consists of membrane 
integrated glycoprotein, gp91phox (NOX2) and p22phox protein. They jointly make up 
the central component of NADPH oxidase complex (Figure 1A). The phagocyte 
NADPH complex also contain four cytosolic components denoted as Ncf1 (p47phox), 
Ncf2 (p67phox), Ncf4 (p40phox) and the small G-protein Rac1 or Rac2 [235], which 
play a regulatory role (Figure 5A). In the resting state, this cytosolic Phox-protein 
complex is inactive due to Ncf1 auto-inhibited conformation. Upon activation 
(exposure to microbes or inflammatory mediators), there is an exchange of GDP for 
GTP on Rac leading to its activation. Additionally, the p47phox becomes heavily 
phosphorylated releasing the auto-inhibitory confirmation, which enables the whole 
Phox-protein translocation and binding to flavocytochrome b558 [236]. The active 
enzyme complex transports electrons from cytoplasmic NADPH to extracellular or 
phagosomal oxygen to generate the ROS superoxide (O2−) molecules (Figure 5B).  
 
 
 
Figure 5. NADPH complex consists of membrane flavocytochrome b558 (NOX2 and p22phox 
protein), cytosolic components Ncf1, Ncf2, Ncf4 and the small G-protein Rac1 or Rac2 (A). 
Upon activation, there will be GDP exchange to GTP on Rac leading to its activation. 
Phosphorylated Ncf1 releases the auto-inhibitory confirmation and enables the whole complex 
translocation to flavocytochrome b558. The active enzyme complex transports electrons from 
cytoplasmic NADPH to extracellular or phagosomal oxygen to generate ROS.  
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10.3 ROS/RNS GENERATION 
ROS and RNS are derived from the Nox/Duox enzymes. Superoxide (O2−) is generated 
by the Nox enzymes and can be converted to hydrogen peroxide (H2O2), either 
spontaneously or by the action of superoxide dismutase (SOD), or alternatively can 
react with nitric oxide (NO) to produce peroxynitrite (ONOO−). H2O2 generated by the 
Duox enzymes or by dismutation of O2− can be scavenged by the antioxidants catalase 
(CAT) or glutathione peroxidase (GPx) and form water (H2O) and oxygen (O2); be 
partially reduced to generate hydroxyl radical (OH) by the metal (Fe3+) catalyzed 
Haber-Weiss and Fenton reactions or react with chloride in a reaction catalyzed by 
myeloperoxidase (MPO) resulting in the formation of hypochlorous acid (HOCl) 
[237](Figure 6). 
 
Figure 6. Schematic representation of ROS/RNS generation in macrophages, where 
superoxide (O2−), nitric oxide (NO), peroxynitrite (ONOO−), water (H2O), hydroxyl 
radical (OH) and (HOCl) are formed by the action of NOX1-5, DUO1/2 enzymes, 
antioxidants as superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase 
(GPx), myeloperoxidase (MPO) and the metal (Fe3+). 
 
10.4 ROS PROTECTION 
There are a number of clinical and experimental observations that implicate immuno-
regulatory role of ROS in inflammatory diseases in contrast to traditional view of 
damaging effects of ROS. As described previously, CGD patients are more prone to 
development of different autoimmune diseases. Hyung-Ran Kim et al demonstrated 
that elevated levels of ROS due to defects in GPx1 and catalase (Cat) in GPx1−/− × 
Cat−/− mice were resistant to Dextran Sodium Sulfate (DSS)-induced colitis. 
Additionally, administration of n-acetyl cysteine (NAC) reduced Treg functions and 
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made GPx1−/− × Cat−/− mice susceptible to DSS-induced colitis [238]. Similarly, GPx1 
deficiency in mice attenuated allergen-induced airway inflammation by suppressing 
Th2 and Th17 cell development [239]. In another independent study by Won et al it 
was shown that ablation of Prx II (non-enzymatic cellular anti-oxidant, peroxiredoxin) 
in mice attenuates colitis by increasing Treg function [240]. Most recently, Tiago 
Rodrigues-Sousa et al suggested lowered ROS association to severe chronic DSS-
Induced Colitis in Ncf1/p47phox-mutant mice, mediated by local accumulation of 
peroxynitrites, pro-inflammatory cytokines and lymphocytes, and systemic immune 
deregulation similar to CGD [241]. Based on all these recent studies, ROS level is 
suspected to be associated with T cell /Treg responsiveness. Previously, reduced ROS 
levels were shown to be associated with autoimmune arthritis and encephalomyelitis 
using autoimmune disease prone Ncf1 gene mutated mouse strain, in which Ncf1 gene 
encoding the p47phox subunit of the NOX2 complex was dysfunctional leading to 
significantly lowered ROS production [102]. Ncf1 was identified as a regulator of 
autoimmune arthritis in rodents and [242] as later studies showed decreased ROS levels 
were associated with an increased number of cell surface thiol groups on T cells, which 
enhanced their arthritogenicity significantly [243]. Even more, macrophage-specific 
ROS production was suppressing T cell responses and thereby arthritis development 
[244]. Hypo-functional Tregs in reduced ROS conditions have been suggested before 
[245] and recently Hyung-Ran Kim et al demonstrated Treg hyper-functionality in 
elevated levels of ROS in IMQ-induced PD (Psoriasis dermatitis) model. Treg hyper-
functionality to high levels of ROS is suggested to operate as a compensatory 
mechanism to overcome ROS damaging effect, as Tregs are able to suppress the 
immune responses, including functions of Th1, Th2, Th17, B, NK cells and DCs and 
thereby decrease psoriasis. Thus, restoration of impaired Treg functions could be a 
possible therapeutic strategy for psoriasis [246]. 
Similarly, successful treatment of psoriasis vulgaris patients by HBOT (hyperbaric 
oxygen therapy) was demonstrated previously [247]. Furthermore, HBOT attenuated 
IMQ-induced PD, while NAC (N-acetyl cysteine) aggravated it [246]. It is 
acknowledged that HBOT increases cellular level of ROS [248]. Recent studies also 
demonstrated the effect of photo (chemo) therapy in increasing Treg functions and 
reducing circulating Th17 cells [249]. Since it is known that phototherapy generates 
ROS levels [250] it allows for the consideration that elevated ROS might be the driving 
mechanism for Treg hyper-functionality.  
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11 NCF1 AS A REGULATOR OF MANNAN-INDUCED PS/PSA IN MICE 
Recently, we have developed a new mouse model for psoriasis (Ps) and psoriasis 
arthritis (PsA)-like disease in mice, where a single injection of mannan i.p. induced an 
acute disease. We have characterized this model in ROS sufficient and deficient 
conditions using B10Q (Ncf1wt/wt) and B10Q.Ncf1mlj/mlj mice respectively. We found 
that disease severity was independent of adaptive immunity and certain acute 
inflammation-driving cell types [185]. Interestingly, macrophage-produced TNF-α was 
a trigger factor for γδ T-cell activation and consequent IL-17A production. We have 
observed that monocyte/macrophage-derived ROS had immuno-regulatory effect in 
Ncf1m1j/m1j.MN+ mice, which expresses functional Ncf1 in macrophages only [185]. 
Similarly, β1,3-glucan of Alcaligenes faecalis-induced ROS from monocytes was also 
shown to suppress innate inflammation [251]. Moreover, ROS protective function was 
shown in other human skin diseases, like scleroderma [252]. Importance of 
macrophages and neutrophils in mannan initiated disease pathogenesis was shown with 
depletion experiments using clodronate liposomes (CLs) or anti-Ly6G antibodies [185]. 
Additionally, we measured mannan stimulated ROS/RNS at cell (blood granulocytes) 
and organ (hind paws) level in B10Q, B10Q.Ncf1m1j//m1j.MN+ and B10Q.Ncf1m1j//m1j 
mice, where produced ROS correlated with relatively milder peripheral joint arthritis 
phenotypes, while ROS deficiency promoted a more aggressive disease. Thus, in 
mannan-induced disease model, increased ROS levels in Ncf1wt/wt mice was correlated 
with partial or complete protection of Ps phenotypes, while ROS deficiency in 
Ncf1mlj/mlj mice was associated with severe Ps disease. 
 
Figure 7. Ps susceptibility is dependent on ROS levels in mannan-induced disease model. 
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Hence, our data show that ROS production by a functional NOX2 is critical for 
attenuating Ps and accompanying joint phenotypes, but the mechanism whereby ROS 
protection operates needs to be investigated further in detail. It is most likely to be 
different from autoimmune arthritis, where αβ T cells play a critical role under the 
regulatory control of macrophage-produced ROS [244] and also different from IMQ-
PD model where ROS mediated prevention of Ps is operating through enhanced IDO 
(indoleamine 2,3-dioxygenase) expression and Treg functions [246]. 
 
 
Modified version of the above section on Ps (chapter II) is submitted to the journal of 
International Archives of Allergy and Immunology as a review article.  
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12 PRESENT INVESTIGATIONS 
 
12.1 STUDY I 
Pathogenic autoreactive B cells are not negatively selected toward matrix protein 
collagen II 
 
We have addressed the importance of B cell tolerance to collagen type II, which is a 
target in rheumatoid arthritis (RA) and its mouse models. We generated a germline-
encoded anti-collagen type II (CII) IgH replacement anti-C1 B cell mouse strain (ACB) 
to investigate how B cell tolerance to CII is subverted and to further understand 
pathogenesis of RA. Phenotypic analysis revealed that CII-specific B cells were 
surprisingly neither deleted nor anergized. Instead, they were readily detected in all 
lymphoid organs. Spontaneously produced autoantibodies could bind directly to 
cartilage surface without detectable pathology. However, exaggerated arthritis was seen 
after injection of anti-CII Abs specific for other epitopes. In addition, Abs from CII-
specific hybridomas generated from ACB mice induced arthritis. Interestingly, IgH/L 
chain sequence data in B cell hybridomas revealed a lack of somatic mutations in auto-
reactive B cells. The ACB model provides the first possibility, to our knowledge, to 
study B cell tolerance to a matrix protein, and the observations made in the study could 
not be predicted from previous models (Paper I). B cell-reactive epitopes on CII are 
largely shared between human RA and rodent CII-induced arthritis; this study, 
therefore, has important implications for further understanding of pathological 
processes in autoimmune diseases like RA. 
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12.2 STUDY II 
Reactive oxygen species control auto-reactive B cell tolerance in experimental 
arthritis 
 
Mechanisms underlying the breakdown of B cell tolerance are one of the most 
important issues in understanding autoimmune diseases, such as rheumatoid arthritis 
(RA). Using germ line-encoded IgH knock-in mice (B10Q.ACB) having auto-reactive 
B cells specific to the major C1-epitope of type II collagen (CII), we have shown that 
CII-reactive B cells are not negatively selected but rather positively selected. We have 
now observed that these mice are protected from collagen-induced arthritis (CIA). 
Introducing a mutation in Ncf1 leading to deficiency of reactive oxygen species (ROS) 
breaks this strong resistance to CIA. Arthritis in the ROS deficient mice is associated 
with enhanced germinal centre (GC) formation, increased T cell responses and diverse 
antibody repertoire against CII. Notably this break of B cells tolerance is independent 
of FcγRIIb and CD1d influence on autoreactive B cell arthritogenicity. ROS produced 
by macrophages mediate disease suppressive effect and maintain B cell tolerance. 
Thus, we have demonstrated a unique mechanism of maintaining tolerance to self and 
its impact on autoimmune arthritis, which may open up new avenues to better 
understand RA pathogenesis. 
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12.3 STUDY III 
 
Mannan induces ROS regulated, IL-17A dependent psoriasis arthritis-like 
disease in mice  
 
Psoriasis (Ps) and psoriasis arthritis (PsA) are poorly understood common diseases, 
induced by unknown environmental factors, affecting skin and articular joints. A single 
i.p. exposure to mannan from Saccharomyces cerevisiae induced an acute inflammation 
in inbred mouse strains resembling human Ps and PsA-like disease, whereas multiple 
injections induced a relapsing disease. Exacerbation of disease severity was observed in 
mice deficient for generation of reactive oxygen species (ROS). Interestingly, 
restoration of ROS production, specifically in macrophages, ameliorated both skin and 
joint disease. Neutralization of IL-17A, mainly produced by γδT cells, completely 
blocked disease symptoms. Furthermore, mice depleted of granulocytes were resistant 
to disease development. In contrast, certain acute inflammatory mediators (C5, Fc 
receptor III, mast cells, and histamine) and adaptive immune players (αβT and B cells) 
were redundant in disease induction. Hence, we propose that mannan-induced 
activation of macrophages leads to TNF-α secretion and stimulation of local γδT cells 
secreting IL-17A. The combined action of activated macrophages and IL-17A 
produced in situ drives neutrophil infiltration in the epidermis and dermis of the skin, 
leading to disease manifestations. Thus, our finding suggests a new mechanism 
triggered by exposure to exogenous microbial components, such as mannan that can 
induce and exacerbate Ps and PsA. 
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12.4 STUDY IV 
Mannan induced psoriasis and psoriasis arthritis-like disease in mice. 
 
A single intraperitoneal injection of mannan from the bakers yeast, Saccharomyces 
cerevisiae induced psoriasis and psoriasis arthritis-like symptoms in mice. Current 
protocol describes the induction and evaluation procedures of these clinical phenotypes 
in detail. Characteristically, arthritis starts with erythema and edema of ankle and wrist 
joints within 2 days after mannan injection reaching maximum severity on days 4 to 5, 
while psoriasis skin scaling appears from day 3 onwards, which becomes more scaly 
over time and eventually peels off entirely. This model depicts an initial phase of 
inflammatory PsA, where macrophages and γδ-T cells and the secreted IL-17A are the 
major players in the pathogenic process. Short duration and resolution of inflammation 
will help for screening various drug candidates targeting the disease process in psoriasis 
patients. 
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13 CONCLUDING REMARKS 
 
ACB mouse model of arthritis, provides the first possibility, to study B cell tolerance to 
a matrix protein and has important implications for further understanding of 
pathological processes in autoimmune diseases like RA, while B cell-reactive epitopes 
on CII are largely shared between human RA and rodent CII-induced arthritis. We have 
demonstrated a unique mechanism of maintaining tolerance to self and its impact on 
autoimmune arthritis, which helps to understand pathogenic mechanisms in human RA. 
Moreover, we showed the impact of ROS in auto-reactive B cell selection towards 
collagen. 
 
Also, we have established and characterized a new model of psoriasis and psoriasis 
arthritis and suggested a new mechanism triggered by exposure to exogenous microbial 
components, such as mannan. We have demonstrated that the reduced production of 
reactive oxygen species helps in more severe disease symptom(s) stimulation, where 
macrophages and γδ-T cells, and the secreted IL-17A are the major players in the 
pathogenic process. This is an unique model of psoriasis, which is accompanied by the 
joint inflammatory disease, where short duration and resolution of inflammation will 
help in facilitating the screening of various drug candidates targeting the disease 
process in psoriasis and psoriasis arthritis patients. 
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